VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Financial reports

Year	Full-year results	Half-year results	Annual report & accounts
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010

OXB-Investors-results and presentation-image grid 1-832x480px

OXB-Investors-results and presentation-image grid 2-832x480px

OXB-Investors-results and presentation-image grid 3-832x480px